Navigation Links
Novel reference material to standardize gene therapy applications
Date:10/6/2010

New Rochelle, NY, October 6, 2010The introduction of a new, fully characterized viral vector for use as reference material to help standardize gene therapy protocols in research applications and human clinical trials is described in an article in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article, which is published online ahead of print, is available free online at www.liebertpub.com/hum

The growing popularity in the gene therapy community of using recombinant adeno-associated virus (rAAV) vectors as vehicles to transfer a gene of interest into a host cell has led to increasing numbers of human clinical trials and animal studies with rAAV. In the past, the absence of standardizationsuch as for rAAV potency and dosinghave made it difficult for researchers and clinicians to compare their protocols and the results of gene therapy experiments. The availability of this rAAV reference standard will allow vector parameters to be expressed in common units, vector doses administered by different investigators to be normalized to an agreed-upon standard, and laboratories to calibrate their internal standards to a common reference material.

Martin Lock, from the Gene Therapy Program at the University of Pennsylvania (Philadelphia) and colleagues from several major medical and research institutions around the world, describe the development of reference standard in the article "Characterization of a Recombinant Adeno-Associated Virus Type 2 Reference Standard Material."

The American Type Culture Collection will make the rAAV2 reference standard material available to the scientific community. AAV serotype 2 was selected as the basis for the reference material because it is the best characterized AAV subtype. The material has been thoroughly analyzed and found to be free of microbial contamination. During development of the rAAV2 reference standard samples were distributed to 16 laboratories worldwide for extensive analysis and characterization.

"The development of a reference standard for an AAV vector is an important step towards the eventual commercial development of this important vector platform," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Head of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, in Philadelphia.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Scripps Research scientists develop novel test that identifies river blindness
2. Interfering with a double-edged sword: novel anti-inflammatory functions for interferons
3. Novartis and collaborators discover novel antimalarial drug candidate
4. Researchers discover novel mechanism protecting plants against freezing
5. Novel antisense therapies protect primates from lethal Ebola and Marburg viruses
6. Novel bee venom derivative forms a nanoparticle smart bomb to target cancer cells
7. UM researcher identifies novel treatment for pain in sickle cell disease
8. Novel microfluidic HIV test is quick and cheap
9. NIH-supported study finds novel pathway may open doors for new blood pressure treatments
10. Novel protein essential for successful pregnancy
11. UT Southwestern researchers use novel sperm stem-cell technique to produce genetically modified rats
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel reference material to standardize gene therapy applications
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):
(Date:9/19/2017)... (PRWEB) , ... September 19, ... ... York State Department of Financial Services (NYS DFS) cybersecurity regulations have ... banking, finance and insurance organizations operating in the state (“Covered Entities”) to ...
(Date:9/18/2017)... ... September 18, 2017 , ... ... move of the SPIE Digital Library ( http://www.spiedigitallibrary.org ) on 15 August to ... an improved user experience and incorporate a number of enhancements and new features, ...
(Date:9/17/2017)... ... 2017 , ... GeneOne Life Science, Inc. announces that it ... (KMFDS) for an Investigational New Drug application for a Phase I/IIa study of ... study in Korea represents the second clinical trial for GLS-5300. , A ...
(Date:9/14/2017)... ... September 14, 2017 , ... DrugDev , a ... the third annual DrugDev Summit, November 7-8, 2017 in Philadelphia, PA. The DrugDev ... clinical research leaders for best practice case studies, keynote presentations, lively breakout sessions, ...
Breaking Biology Technology: